Sandoz launches new OMNITROPE growth hormone concentration in Egypt
Egypt - Sandoz, a global leader in generic and biosimilar medicines, announced on Sunday the introduction of its 15mg/1.5ml concentration of the OMNITROPE biosimilar growth hormone to the Egyptian market for the treatment of short stature. This initiative aligns with Sandoz's ongoing efforts to support Egypt's Vision 2030 and local healthcare authorities' commitment to enhancing public health.
The company stated that the newly available concentration aims to help expand access to growth hormone, noting that an estimated 17% of Egyptian children suffer from short stature. Research conducted at Suez Canal University's endocrinology outpatient clinic, released in 2024, indicated that growth hormone treatment significantly improves physical, social, psychological, and environmental quality of life.
Dr. Mona Salem, Professor of Paediatric Endocrinology at Ain Shams University and President of the Egyptian Society of Paediatric Endocrinology & Diabetes, said: 'In children and adolescents, growth hormone is used to treat growth disturbance due to insufficient secretion of growth hormone, associated with Turner syndrome, with chronic renal insufficiency, in short children/adolescents born small for gestational age, or associated with Prader-Willi syndrome (PWS). The biosynthetic/synthetic hormone is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (GH).'
Dr. Salem added, 'Short stature is diagnosed in children or adolescents who are well below the average height for their age and gender, which may be due to genetic factors or underlying health conditions. Studies show that short stature prevalence varies geographically, with a genetic predisposition, as well as nutritional and environmental factors, playing an important role.'
A cross-sectional study conducted between January 2018 and January 2020 involving 33,150 Egyptian children aged 6 to 11 showed that 17% of the sample had short stature, with 40.8% attributed to familial factors and 24.2% to constitutional causes.
Dr. Rasha Tarif, Head of the Paediatric Endocrinology Unit at Ain Shams University and Chair of the European Society for Paediatric Endocrinology (ESPE) Education and Training Committee, stated: 'As noted, short stature affects children and adolescents, not only physically but also psychologically. Growth hormone is one of the most effective treatments for the aforementioned growth disturbances. The dosage is carefully calculated based on weight, underlying cause, puberty stage, as well as stimulated growth hormone test results, to achieve the best possible final height outcomes.'
Dr. Tarif emphasised that young patients require therapeutic intervention before growth plates fuse, after which height cannot be gained. She added, 'Growth hormone plays a critical role in effective treatment plans, but ensuring its availability has been a challenge in recent years. This challenge is being addressed through ongoing efforts to secure sufficient quantities to ensure uninterrupted treatment until puberty is complete, and in some cases, for life. Treatment continuity, along with proper follow-up with a specialized physician, is essential for achieving optimal results.'
Sandoz said the new concentration is being made available at an affordable cost, expanding treatment options and aiming for better patient response and an effective, safe treatment journey by minimising interruptions. The company stated that securing the reliable availability of this human growth hormone reinforces medical efforts to provide comprehensive care.
Sameh Elbagoury, Sandoz Egypt Country Head, said: 'The Egyptian government, within the context of the Egypt Vision 2030, has shown strong commitment to reducing the prevalence of short stature among children, aiming to improve public health for current and future generations, and help build a healthier, more productive workforce, in line with the national vision for sustainable development.'
Elbagoury added: 'Our top priority at Sandoz is to develop affordable biosimilars for high-quality biologics and ensure that as many patients as possible have access to them. Introducing the 15mg concentration of our well-established Omnitrope growth hormone allows us to help local authorities meet the increase in demand for growth hormones, reflecting the positive impact and notable success achieved by the Presidential Initiative for the Early Detection of Anaemia, Obesity and Short Stature.'
Sandoz Omnitrope received approval from the US Food and Drug Administration and the European Medicines Agency in 2006, with subsequent approvals in other countries. Sandoz has also established a long-term, post-marketing surveillance programme for the product.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
6 hours ago
- Khaleej Times
From Nigeria to Pakistan, TB testing 'in a coma' after US aid cuts
A t a tense meeting in Nigeria's capital Abuja, health workers poured over drug registers and testing records to gauge whether US aid cuts would unravel years of painstaking work against tuberculosis in one of Africa's hardest hit countries. For several days in May, they brainstormed ways to limit the fallout from a halt to US funding for the TB Local Network (TB LON), which delivers screening, diagnosis and treatment. "To tackle the spread of TB, you must identify cases and that is in a coma because of the aid cuts," said Ibrahim Umoru, coordinator of the African TB Coalition civil society network, who was at the Abuja meeting. "This means more cases will be missed and disaster is looming." This desperate struggle to save endangered programmes is being replicated from the Philippines to South Africa as experts warn that U.S. aid cuts risk reviving a deadly infectious disease that kills around one million people every year. President Donald Trump's gutting of the U.S. Agency for International Development has put TB testing and tracing on hold in Pakistan and Nigeria, stalled vital research in South Africa and left TB survivors lacking support in India. The World Health Organisation says "the drastic and abrupt cuts in global health funding" threaten to reverse the gains made by global efforts to fight the disease - namely 79 million lives saved since 2000 - with rising drug resistance and conflicts exacerbating the risks. In Nigeria, TB LON is in the firing line. The project was set up in 2020, during Trump's first term, and received $45 million worth of funding from USAID. The U.S. development agency said at the time it was committed to a "TB free Nigeria". Five years later and with the same president back in charge but now with a more radical "America first" agenda, USAID support for TB LON's community testing work was terminated in February, according to a TB LON official. The official did not want to be named because he was not authorised to speak on behalf of the project. 'HARD WORK IN JEOPARDY' TB kills 268 Nigerians every day and cases have historically been under-reported increasing the risk of transmission. If one case is missed, that person can transmit TB to 15 people over a year, according to the World Health Organization. The Thomson Reuters Foundation spoke to half a dozen health workers who collect TB test samples for TB LON but had stopped doing so in January due to the U.S. aid freeze. Between 2020-2024, TB LON screened around 20 million people in southwestern states in Nigeria, and more than 100,000 patients were treated as a result. "All that hard work is in jeopardy if we don't act quickly," Umoru said, adding that non-profits working with TB LON had laid off more than 1,000 contract workers who used to do TB screening. Nigeria's health ministry did not respond to request for comment on the effect of the USAID cuts on TB programmes. In March, First Lady Oluremi Tinubu declared TB a national emergency and donated 1 billion naira ($630,680) to efforts to eradicate the disease by 2030. In South Africa, medical charity Médecins Sans Frontières (MSF) said TB and HIV programmes had been disrupted across the country, making patient tracking and testing more difficult, according to a statement sent to the Thomson Reuters Foundation. South Africa had a TB incidence rate of 427 per 100,000 people in 2023, government data showed, down 57% from 2015. TB-related deaths in South Africa dropped 16% over that period, the data showed. Minister of Health Aaron Motsoaledi said in May that the government would launch an End TB campaign to screen and test 5 million people, and was also seeking new donor funding. "Under no circumstances will we allow this massive work performed over a period of more than a decade and half to collapse and go up in smoke," he said at the time, referring to efforts to tackle TB and HIV. BLOW TO CRITICAL RESEARCH South Africa is also a hub for research into both TB and HIV and the health experts say funding cuts risk derailing this vital work. The Treatment Action Group (TAG), a community-based research and policy think tank, says around 39 clinical research sites and at least 20 TB trials and 24 HIV trials are at risk. "Every major TB treatment and vaccine advance in the past two decades has relied on research carried out in South Africa," said TAG TB project co-director Lindsay McKenna in a March statement. People struggling with poor nutrition and those living with HIV -- the latter affects 8 million people in South Africa -- were also more at risk of contracting TB as aid cuts made them more vulnerable by derailing nutrition programmes, community outreach and testing, said Cathy Hewison, head of MSF's TB working group. "It's the number one killer of people with HIV," she said. In the Philippines, U.S. cuts have disrupted TB testing in four USAID-funded projects, and affected the supply of drugs, Stop TB Partnership, a U.N.-funded agency said. "The country has a nationwide problem with recurrent drug shortages, which is leading to a direct impact on efforts to eliminate TB," said Ghazali Babiker, head of mission for MSF Philippines. In Pakistan, which sees 510,000 TB infections each year, MSF said US cuts had disrupted TB screening in communities and other services in the hard-hit southeastern province of Sindh. "We are worried that the U.S. funding cuts that have impacted the community-based services will have a disproportionate effect on children, leading to more children with TB and more avoidable deaths," said Ei Hnin Hnin Phyu, medical coordinator with MSF in Pakistan.
Zawya
10 hours ago
- Zawya
Mozambique: Human Immunodeficiency Virus (HIV) Services Expand to Reach People with Disabilities
Across Mozambique, momentum is building in the delivery of HIV services, bringing renewed opportunities for communities that have long been on the margins. In Beira, one organization is working to ensure that people with disabilities are fully supported in the country's response to HIV. AMAMUS, a local group funded through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), has emerged as a key partner in expanding access to HIV prevention, testing and treatment. Drawing on trusted community ties, the organization quickly ramped up its services earlier this year, reaching both new and existing beneficiaries through tailored approaches. Antonia Piri Piri, AMAMUS Coordinator and a respected advocate who also lives with hearing impairment said that they were ready to reach out to beneficiaries who depend on them not only for healthcare but also for reassurance, understanding, and a sense of connection. She added that as soon as it was possible, they returned to the neighborhoods to ensure that no one was left behind. Bringing Services Closer to Those Often Overlooked In Mozambique, roughly 2% of the population lives with a disability—a group that routinely faces barriers in the health system. The 2017 census found that 9.4% of people with disabilities have hearing impairments, with more than 14,000 living in Sofala Province, where AMAMUS is most active. One of the many touched by the organization's work is Joana Antonio, 26. Blind since childhood, Joana had never taken an HIV test due to fear, misinformation, and the lack of accessible information. With guidance from AMAMUS, she used a self-test kit for the first time and learned she was living with both HIV and tuberculosis. She was quickly linked to treatment and continues to receive support. Joana said that although she was initially scared to find out her status, she received support and guidance from AMAMUS, which helped her understand everything. She now knows her status and is receiving the care she needs. Privacy, Dignity and Health at Home A central part of AMAMUS's outreach is the promotion of HIV self-testing, an empowering tool for individuals who face obstacles visiting health centers. The kits are distributed through door-to-door outreach, community visits, and awareness sessions, where AMAMUS activists demonstrate how to use them safely and privately. For people with disabilities, this approach removes hurdles like long travel, communication barriers, and the need for intermediaries. If a test is positive, AMAMUS steps in to provide counseling, confirmatory testing, and referrals to care. They also offer psychosocial support and help escort individuals to clinics when needed. Creating a Health System That Reflects Everyone Despite progress, structural challenges persist. Many health facilities are not adapted for those with mobility, visual, or auditory impairments. Public transportation remains inconsistent and discriminatory, sometimes charging extra for assistive devices or refusing service altogether. These gaps hinder consistent access to treatment and increase the risk of drug resistance. AMAMUS is working to overcome these hurdles by advocating for more representation in health planning and by adapting their own services to meet people where they are. For AMAMUS, this is about more than just physical access—it's about visibility, voice, and respect. Tech Tools Build Community Engagement AMAMUS is also using digital tools to build stronger connections. The organization created WhatsApp groups tailored to different communities, providing real-time updates on HIV services and creating a space for peer support. A community health fair is also in the works, designed to bring integrated services like HIV testing directly to residents in hard-to-reach areas. Progress Anchored in Community Strength As Mozambique intensifies its HIV response, organizations like AMAMUS are playing a vital role in ensuring that services reach all corners of society. Their work is helping to dismantle long-standing barriers and foster broad-based participation in health initiatives. While a temporary pause in activities earlier this year posed logistical challenges, it also reinforced the value of community-rooted responses and the urgency of building health systems that serve everyone, regardless of ability or background. Distributed by APO Group on behalf of U.S. Embassy in Mozambique.
Khaleej Times
10 hours ago
- Khaleej Times
Liv Hospital City Walk achieves landmark JCI 8th Edition accreditation
Liv Hospital City Walk, the first Middle East venture of one of Turkey's largest private healthcare networks, MLPCare, has marked a major milestone in its early journey by securing accreditation under the Joint Commission International's (JCI) newly released 8th Edition standards. The achievement places the Dubai-based hospital among the first in the region to be recognised under these elevated global criteria for patient safety, clinical governance, and health service continuity. Located in the heart of City Walk, Liv Hospital officially opened its doors in late 2024. It has since grown into a 24/7 facility staffed by over 60 physicians and nearly 200 healthcare professionals, providing multidisciplinary care across a range of medical specialties. Backed by over 25 years of medical expertise in Turkey and Europe, the hospital integrates academic rigor with advanced clinical services to serve a rapidly growing patient population in the UAE. The JCI 8th Edition standards, introduced to reflect modern healthcare challenges, place increased emphasis on digital health, sustainability, risk management, and integrated patient-centric care. Liv Hospital City Walk's accreditation under this framework underscores its commitment to continuous improvement and high standards in service delivery. 'Achieving accreditation under JCI's 8th Edition is more than recognition — it is a reflection of our deeply rooted culture of clinical quality and operational integrity,' said Dr Özgun Güngör, general surgery specialist and general manager of Liv Hospital City Walk. 'This milestone represents a collective commitment to excellence by our medical and administrative teams. As Liv Hospital's representative in the UAE, I am proud of the progress we've made in such a short time.' Liv Hospital City Walk is the latest development in MLPCare's growing international footprint, which spans over 38 hospitals across Turkey, the UK, Hungary, Kosovo, and Azerbaijan. The expansion into Dubai reflects the group's long-term vision of delivering high-quality, ethical, and technologically advanced healthcare to global communities. Developed in close academic collaboration with Istinye University, the hospital benefits from a robust academic ecosystem. Graduates from the university's faculties of medicine, dentistry, and nursing now contribute to the hospital's clinical depth, helping foster a practice that is grounded in evidence-based medicine and innovation. Liv Hospital City Walk offers advanced care in key medical areas such as interventional cardiology, neuro and spine surgery, general surgery, gastroenterology, dental services, and aesthetic medicine. The hospital's patient-centered model emphasises collaborative diagnosis and treatment planning, with safety and transparency at its core. In a short span, the facility has emerged as a regional center of excellence—attracting both local and international patients seeking high standards of personalised care and medical expertise. Part of the MLPCare international healthcare network, Liv Hospital City Walk is located in Dubai's City Walk district and delivers comprehensive, round-the-clock medical services. The hospital combines clinical excellence, modern infrastructure, and academic collaboration to set new standards in ethical and evidence-based healthcare across the region.
